<?xml version="1.0" encoding="UTF-8"?>
<p>Very recently, the AIDS Clinical Trials Group A5258 was completed. It was a randomized, double-blind, placebo-controlled study in 33 HIV-1-infected participants off antiretroviral therapy and 37 participants on antiretroviral therapy. CQ modestly reduced immune activation in antiretroviral therapy-treated HIV-infected participants [
 <xref rid="B42-microorganisms-08-00085" ref-type="bibr">42</xref>].
</p>
